Literature DB >> 17436099

X-linked hyper-IgM syndrome associated with poorly differentiated neuroendocrine tumor presenting as obstructive jaundice secondary to extensive adenopathy.

Nandini Nagaraj1, Chukwuma Egwim, Douglas G Adler.   

Abstract

X-Linked Hyper IgM Syndrome (XHIGM) is a rare B-cell immunodeficiency disease. Patients with XHIGM are unable to switch immunoglobulin production from IgM to IgG, IgA, and IgE. Patients with XHIGM require periodic intravenous immune globulin to help prevent infections, and are also at risk for a variety of neoplasms. We describe a young man with XHIGM who presented with obstructive jaundice from malignant adenopathy from widespread, poorly differentiated neuroendocrine tumor. This has not previously been reported and represents a new association with XHIGM.

Entities:  

Mesh:

Year:  2007        PMID: 17436099     DOI: 10.1007/s10620-006-9702-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Clinical spectrum of X-linked hyper-IgM syndrome.

Authors:  J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

Review 2.  Hyper IgM syndrome: the other side of the coin.

Authors:  R L Fuleihan
Journal:  Curr Opin Pediatr       Date:  2001-12       Impact factor: 2.856

3.  Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM.

Authors:  R Fuleihan; N Ramesh; R Loh; H Jabara; R S Rosen; T Chatila; S M Fu; I Stamenkovic; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

Review 4.  Endocrine tumours of the gastrointestinal tract: Chemotherapy.

Authors:  R Arnold; A Rinke; Ch Schmidt; L Hofbauer
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-08       Impact factor: 3.043

5.  Cryptococcal meningitis in a patient with X-linked hyper-IgM1 syndrome.

Authors:  Miguel de Górgolas; Alejo Erice; Antonio Gil; Javier Gutiérrez; Pablo Rivas; Carlos Hernando; Ma Cruz García Rodríguez
Journal:  Scand J Infect Dis       Date:  2005

6.  Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome.

Authors:  Sheng-Chieh Lin; Shyh-Dar Shyur; Yi-Chun Ma; Li-Hsin Huang; Hung-Chang Lee; Wen-I Lee
Journal:  J Formos Med Assoc       Date:  2005-06       Impact factor: 3.282

7.  CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM.

Authors:  J P DiSanto; J Y Bonnefoy; J F Gauchat; A Fischer; G de Saint Basile
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

Review 8.  The treatment of undifferentiated neuroendocrine tumors.

Authors:  E Mitry; P Rougier
Journal:  Crit Rev Oncol Hematol       Date:  2001-01       Impact factor: 6.312

9.  CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome.

Authors:  L D Notarangelo; M C Peitsch; T G Abrahamsen; C Bachelot; P Bordigoni; A J Cant; H Chapel; M Clementi; S Deacock; G de Saint Basile; M Duse; T Espanol; A Etzioni; A Fasth; A Fischer; S Giliani; L Gomez; L Hammarstorm; A Jones; M Kanariou; C Kinnon; T Klemola; R A Kroczek; J Levy; N Matamoros; V Monafo; P Paolucci; I Reznick; O Sanal; C I Smith; R A Thompson; P Tovo; A Villa; M Vihinen; J Vossen; B J Zegers
Journal:  Immunol Today       Date:  1996-11

Review 10.  Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy.

Authors:  Silvia Della Torre; Giuseppe Procopio; Alberto Fusi; Laura Catena; Leonardo Ferrari; Paola Nova; Angela Denaro; Ettore Bichisao; Emilio Bajetta
Journal:  Tumori       Date:  2003 Mar-Apr
View more
  1 in total

Review 1.  Immunodeficiencies.

Authors:  M Ballow; L Notarangelo; B Grimbacher; C Cunningham-Rundles; M Stein; M Helbert; B Gathmann; G Kindle; A K Knight; H D Ochs; K Sullivan; J L Franco
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.